Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma: early-phase trial registry
88 of 330 indexed Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #21 of 28,707 conditions by registered trial count.
330 US clinical trials · 88 currently recruiting · #21 of 28,707 conditions by registered trial count
Lymphoma: 330 US clinical trials tracked, 88 recruiting.
Lymphoma is the subject of 330 registered US clinical trials on ClinicalTrials.gov, 88 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 229 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition lymphoma
OPEN 88 | RECR 27% | LATE 25 | EARLY 229 | RANK #21 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)
Lymphoma lists 88 open slots (27% of 330 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma is recruiting below its size-band peers.
88 of 330 indexed trials (26.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 330 trials (10.3%). 116 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 300 trials that report a genuine target (sentinel values excluded). 213 of those (71%) plan for fewer than 100 participants.
-
Lymphoma research is mostly interventional.
299 interventional and 31 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
330 total, page 3 of 7
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
NCT01446133
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
NCT02783625
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT01511562
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
M.D. Anderson Cancer Center
NCT05464823
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
NCT01352520
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Seattle Children's Hospital
NCT03330691
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
M.D. Anderson Cancer Center
NCT04270266
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
Memorial Sloan Kettering Cancer Center
NCT01697930
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
NCT03502733
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax
NCT04977024
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Baylor College of Medicine
NCT00881920
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
NCT03995147
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
St. Jude Children's Research Hospital
NCT06053268
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Emory University
NCT06328699
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT03747757
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
NCT03179930
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT04980222
An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer
Memorial Sloan Kettering Cancer Center
NCT03794635
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT03602157
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
NCT04571138
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT05540340
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
NCT02690545
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
Masonic Cancer Center, University of Minnesota
NCT04514029
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
NCT01744223
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
M.D. Anderson Cancer Center
NCT06049134
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
University of Chicago
NCT05019976
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
Memorial Sloan Kettering Cancer Center
NCT03352765
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
NCT00641381
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Memorial Sloan Kettering Cancer Center
NCT03793140
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT05495464
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
NCT03480360
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05763563
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT03696784
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
NCT01430390
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT02663297
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
NCT04608487
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Seattle Children's Hospital
NCT03684889
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT03264131
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT02932280
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
NCT04088864
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT02477878
A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05081479
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
Baylor College of Medicine
NCT00368082
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
Stanford University
NCT03245788
SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
SWOG Cancer Research Network
NCT01000558
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development
NCT01855750
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
NCT00003150
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
NCT00006721
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Mayo Clinic
NCT00661999
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
Radiation Therapy Oncology Group
NCT00053053
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 110 |
| Phase 3 | 22 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma page
330 registered trials, 88 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 88 Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma condition card totals 330 registered trials; most-linked intervention cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.